Drug Profile
Pegtibatinase - Travere Therapeutics
Alternative Names: htCBS C15S ME-200GS; OT-58; PEG htCBS C15S; PEG modified CBS; TVT-058Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Orphan Technologies
- Developer Orphan Technologies; Travere Therapeutics
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Homocystinuria
Most Recent Events
- 14 Dec 2023 Phase-III clinical trials in Homocystinuria (In adolescents, In adults) in USA (SC) (NCT06247085)
- 14 Dec 2023 Travere Therapeutics plans the phase IIIb ENSEMBLE trial in Homocystinuria (SC)
- 31 May 2023 Efficacy and adverse events data from a phase I/II COMPOSE trial in Homocystinuria released by Travere Therapeutics